EIKN
Eikon Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.95
+4.07%Income statement
| Metric | TTM | 2025 |
|---|---|---|
| Revenue | ||
| Total Revenue | — | — |
| Cost of Revenue | 15.2M | 24.2M |
| Gross Profit | (15.2M) | (24.2M) |
| Operating Expenses | ||
| R&D Expense | 270.0M | 250.3M |
| SG&A Expense | 58.5M | 88.6M |
| General & Admin Expense | 33.4M | 88.6M |
| Selling & Marketing Expense | — | — |
| Other Expenses | (5.1M) | (24.2M) |
| Total Operating Expenses | 323.4M | 314.8M |
| Cost and Expenses | 338.6M | 338.9M |
| Operating Income (EBIT) | (338.6M) | (338.9M) |
| Non-Operating | ||
| Interest Income | 12.9M | 15.6M |
| Interest Expense | — | 837.0K |
| Net Interest Income | 12.9M | 14.7M |
| Other Non-Op Income/Expense | 16.5M | 14.7M |
| Non-Operating Income (excl Interest) | (20.0M) | (15.5M) |
| EBT (Pre-Tax Income) | (322.2M) | (324.2M) |
| Income Tax Expense | — | — |
| Bottom Line | ||
| Net Income | (322.2M) | (324.2M) |
| Earnings from Cont. Ops | (322.2M) | (324.2M) |
| Earnings from Discont. Ops | — | — |
| Bottom Line Net Income | (322.2M) | (333.6M) |
| Per Share | ||
| Basic EPS | ($4.63) | ($6.16) |
| Diluted EPS | ($4.63) | ($6.16) |
| Revenue Per Share | $0.00 | $0.00 |
| Shares | ||
| Basic Shares Outstanding | 54.1M | 54.1M |
| Diluted Shares Outstanding | 54.1M | 54.1M |
| Profitability Metrics | ||
| EBITDA | (297.1M) | (299.2M) |
| D&A | 21.5M | 24.2M |
| EBIT | (318.7M) | (323.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026